Ocugen Licenses OCU400 MENA Rights to Roots in Agreements
Ocugen signed two agreements with Roots Pharmaceutical Company to advance OCU400 for retinitis pigmentosa across the Middle East and North Africa. The headline reports a 22% royalty and milestone payments of up to $259 million.
Ocugen signed two agreements with Roots Pharmaceutical Company to advance OCU400 for retinitis pigmentosa across the Middle East and North Africa. The Exclusive License Agreement grants Roots regional rights while Ocugen receives an upfront fee, up to $4 million in regulatory and development milest…